£40.5 million invested in discovery platform and to advance pipeline 

GBP pound sterling funding

Curve Therapeutics, a company developing an intracellular screening platform to address disease targets, has completed a £40.5 million ($51.37 million) Series A financing round.

Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and co-lead from the seed round, Epidarex Capital. 

Curve’s Microcycle platform enables the direct discovery of biologically active molecules against targets that have been difficult to address using conventional drug discovery methods. Curve has built a discovery pipeline of assets including a first-in-class dual-inhibitor of HIF-1 and HIF-2 that addresses survival mechanisms in more than half of solid tumours, and a first-in-class inhibitor of ATIC dimerisation that targets an important vulnerability in multiple cancers. The financing will enable the company to progress development of these assets rapidly towards clinical development and to expand the discovery platform beyond challenging and complex intracellular protein targets. 

Simon Kerry, Chief Executive Officer of Curve Therapeutics, said: “This financing will enable us to expand our team, progress our lead assets into the clinic and to expand our drug discovery platform. We welcome our new investors alongside our existing strong syndicate and look forward to working together to take Curve to its next stage of growth.” 

Professor Ali Tavassoli, Chief Scientific Officer of Curve Therapeutics, added: “Curve’s Microcycle platform is a powerful tool for drug discovery, enabling an unparalleled advantage in the discovery of functional hits and leads. We look forward to maximising the potential of our platform to further develop a rich pipeline of programmes with the potential to treat unmet clinical needs in a diverse range of diseases, including cancer.” 

Dr Marie-Claire Peakman, Partner at Pfizer Ventures, commented: “We are delighted to have led this financing and to work with great co-investors and leadership team. Curve’s platform provides an exciting new approach designed to tackle tough, high priority targets which have been difficult to progress in the past. We are eager for the company to progress the platform with the goal of identifying new therapeutics for challenging diseases.” 

Megan Thomas, Multimedia Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free